Regeneron’s siRNA therapy cemdisiran received FDA approval as Livsayis for myasthenia gravis, marking the second myasthenia-gravis drug approval in a week and underscoring the agency’s growing comfort with RNAi modalities. The approval places a new mechanism in the standard-of-care mix for myasthenia gravis, alongside established immunotherapies and symptomatic regimens. Livsayis’ arrival adds to momentum for next-generation targeted gene-silencing therapies aimed at reducing the underlying drivers of autoimmune disease rather than only treating symptoms. For clinicians and development teams, the label outcome also signals continued regulatory openness to manufacturing- and delivery-focused RNAi platforms where dosing logistics and durability of effect are key commercial and practical differentiators.